MX2011009810A - Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor. - Google Patents
Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor.Info
- Publication number
- MX2011009810A MX2011009810A MX2011009810A MX2011009810A MX2011009810A MX 2011009810 A MX2011009810 A MX 2011009810A MX 2011009810 A MX2011009810 A MX 2011009810A MX 2011009810 A MX2011009810 A MX 2011009810A MX 2011009810 A MX2011009810 A MX 2011009810A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- binding proteins
- binding
- fgf
- bispecific
- Prior art date
Links
- 108091008324 binding proteins Proteins 0.000 title abstract 4
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000023732 binding proteins Human genes 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 abstract 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 abstract 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 abstract 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 101710146873 Receptor-binding protein Proteins 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16402309P | 2009-03-27 | 2009-03-27 | |
| PCT/US2010/028877 WO2010111625A1 (en) | 2009-03-27 | 2010-03-26 | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011009810A true MX2011009810A (es) | 2011-09-30 |
Family
ID=42332479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011009810A MX2011009810A (es) | 2009-03-27 | 2010-03-26 | Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120134993A1 (OSRAM) |
| EP (1) | EP2411407A1 (OSRAM) |
| JP (1) | JP2012521768A (OSRAM) |
| KR (1) | KR20110134494A (OSRAM) |
| CN (1) | CN102448984A (OSRAM) |
| AU (1) | AU2010229705A1 (OSRAM) |
| MX (1) | MX2011009810A (OSRAM) |
| WO (1) | WO2010111625A1 (OSRAM) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
| MX2015012778A (es) * | 2013-03-15 | 2016-01-20 | Intermune Inc | Marcadores proteomicos de fibrosis pulmonar idiopatica (fpi). |
| EP3013851A4 (en) * | 2013-06-25 | 2016-12-28 | Sépia Pesquisa E Desenvolvimento | MODULATORS OF BRADYKININ RECEPTORS AND THEIR USE |
| US9879081B2 (en) | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
| KR102060187B1 (ko) | 2013-07-19 | 2019-12-27 | 삼성전자주식회사 | Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도 |
| PL3041513T3 (pl) | 2013-09-08 | 2021-01-25 | Kodiak Sciences Inc. | Obojnaczojonowe polimerowe koniugaty czynnika viii |
| WO2015200905A2 (en) * | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CN104177492B (zh) * | 2014-07-21 | 2017-02-22 | 暨南大学 | FGFR2c胞外段类似物及其编码基因与应用 |
| CN113957146A (zh) | 2014-09-26 | 2022-01-21 | 詹森药业有限公司 | 使用fgfr突变基因组鉴定将对用fgfr抑制剂进行治疗有反应的癌症患者 |
| KR102210104B1 (ko) | 2014-10-17 | 2021-02-01 | 코디악 사이언시스 인코포레이티드 | 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트 |
| US12428483B2 (en) | 2014-12-22 | 2025-09-30 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| WO2016106158A1 (en) | 2014-12-22 | 2016-06-30 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| UA128057C2 (uk) | 2015-07-15 | 2024-03-27 | Ґенмаб А/С | Гуманізоване або химерне антитіло, яке зв'язує cd3 людини |
| WO2017091850A1 (en) * | 2015-11-30 | 2017-06-08 | Pieris Australia Pty Ltd. | Novel anti-angiogenic fusion polypeptides |
| CA3010056A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| WO2018011421A1 (en) | 2016-07-14 | 2018-01-18 | Genmab A/S | Multispecific antibodies against cd40 and cd137 |
| PT3592769T (pt) | 2017-03-09 | 2024-07-31 | Genmab As | Anticorpos contra pd-l1 |
| UA127586C2 (uk) | 2017-03-31 | 2023-10-25 | Ґенмаб Холдінґ Б.В. | Біспецифічні анти-cd37-антитіла, моноклональні анти-cd37-антитіла та способи їх застосування |
| CN111406067B (zh) | 2017-08-04 | 2022-11-08 | 健玛保 | 与pd-l1和cd137结合的结合剂及其用途 |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| US12077586B2 (en) | 2018-09-19 | 2024-09-03 | LAVA Therapeutics N.V. | Bispecific antibodies for use in the treatment of hematological malignancies |
| MA53812A (fr) | 2018-10-04 | 2021-08-11 | Genmab Holding B V | Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques |
| KR20210124959A (ko) | 2018-11-06 | 2021-10-15 | 젠맵 에이/에스 | 항체 제제 |
| NL2022494B1 (en) | 2019-02-01 | 2020-08-19 | Lava Therapeutics B V | Novel CD40-binding antibodies |
| EP3917960A1 (en) | 2019-02-01 | 2021-12-08 | LAVA Therapeutics N.V. | Novel cd40-binding antibodies |
| JPWO2021010326A1 (OSRAM) * | 2019-07-12 | 2021-01-21 | ||
| EP3792283A1 (en) | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| WO2021155916A1 (en) | 2020-02-04 | 2021-08-12 | BioNTech SE | Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137 |
| MY210125A (en) | 2020-03-18 | 2025-08-28 | Genmab As | Antibodies binding to b7h4 |
| JP2023524149A (ja) | 2020-05-08 | 2023-06-08 | ジェンマブ エー／エス | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
| US20230272110A1 (en) | 2020-07-08 | 2023-08-31 | LAVA Therapeutics N.V. | Antibodies that bind psma and gamma-delta t cell receptors |
| JP2023536340A (ja) | 2020-08-06 | 2023-08-24 | ビオンテック・ソシエタス・エウロパエア | コロナウイルスｓタンパク質のための結合剤 |
| BR112023004327A2 (pt) | 2020-09-10 | 2023-04-04 | Genmab As | Método para tratar leucemia linfocítica crônica em um sujeito humano |
| MX2023002545A (es) | 2020-09-10 | 2023-03-14 | Genmab As | Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para el tratamiento de linfoma difuso de celulas b grandes. |
| JP2024501403A (ja) | 2020-12-10 | 2024-01-12 | ラヴァ・セラピューティクス・エヌ・ヴイ | ガンマ－デルタｔ細胞受容体に結合する抗体 |
| US20240141071A1 (en) | 2021-02-26 | 2024-05-02 | LAVA Therapeutics N.V. | Antibodies that bind cd123 and gamma-delta t cell receptors |
| US20240383982A1 (en) | 2021-05-07 | 2024-11-21 | Genmab A/S | Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3 |
| IL309319A (en) | 2021-06-21 | 2024-02-01 | Genmab As | Combined dosage regimen CD137 and PD-L1 binding agents |
| TW202328193A (zh) | 2021-09-13 | 2023-07-16 | 美商健生生物科技公司 | 用於治療癌症的CD33 x Vδ2多特異性抗體 |
| AU2022361691A1 (en) | 2021-10-08 | 2024-03-28 | Genmab A/S | Antibodies binding to cd30 and cd3 |
| EP4419109A1 (en) | 2021-10-21 | 2024-08-28 | LAVA Therapeutics N.V. | Uses of gamma delta t cell activating antibodies |
| WO2023174521A1 (en) | 2022-03-15 | 2023-09-21 | Genmab A/S | Binding agents binding to epcam and cd137 |
| EP4285926A1 (en) | 2022-05-30 | 2023-12-06 | LAVA Therapeutics N.V. | Combination treatment for chronic lymphocytic leukemia |
| EP4292609A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Compositions comprising antibodies that bind gamma-delta t cell receptors |
| EP4292610A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| NL2032398B1 (en) | 2022-07-06 | 2024-01-23 | Academisch Ziekenhuis Leiden | Bispecific antibody and uses thereof |
| CN118420715B (zh) * | 2023-03-23 | 2025-01-24 | 湖南中晟全肽生物科技股份有限公司 | 一种结合fgfr2受体的多肽及其用途 |
| EP4438624A1 (en) | 2023-03-27 | 2024-10-02 | LAVA Therapeutics N.V. | Antibodies that bind nectin-4 and gamma-delta t cell receptors |
| WO2024200573A1 (en) | 2023-03-27 | 2024-10-03 | LAVA Therapeutics N.V. | Nectin-4 binding agents and methods of use |
| AR132290A1 (es) | 2023-04-05 | 2025-06-11 | Genmab As | Composiciones farmacéuticas que comprenden anticuerpos que se unen a cd30 y cd3 |
| WO2025003280A1 (en) | 2023-06-30 | 2025-01-02 | Genmab A/S | Antibodies binding to fibroblast activation protein alpha and death receptor 4 |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| WO2025024780A1 (en) | 2023-07-27 | 2025-01-30 | LAVA Therapeutics N.V. | Antibodies that bind gamma-delta t cell receptors for the treatment of cancer |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004536579A (ja) * | 2001-04-13 | 2004-12-09 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 血管内皮増殖因子２ |
| WO2003020906A2 (en) * | 2001-08-31 | 2003-03-13 | Abmaxis, Inc. | Multivalent protein conjugate with multiple ligand-binding domains of receptors |
| WO2005087812A1 (en) * | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
| CN1997382A (zh) * | 2004-05-05 | 2007-07-11 | 梅里麦克制药股份有限公司 | 调节生物活性的双特异性结合剂 |
| EP1910542B1 (en) * | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| US20090304719A1 (en) * | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| PL2274008T3 (pl) * | 2008-03-27 | 2014-07-31 | Zymogenetics Inc | Kompozycje i sposoby hamowania PDGFRbeta i VEGF-A |
-
2010
- 2010-03-26 KR KR1020117025299A patent/KR20110134494A/ko not_active Ceased
- 2010-03-26 CN CN2010800230893A patent/CN102448984A/zh active Pending
- 2010-03-26 AU AU2010229705A patent/AU2010229705A1/en not_active Abandoned
- 2010-03-26 EP EP10722828A patent/EP2411407A1/en not_active Ceased
- 2010-03-26 US US13/260,408 patent/US20120134993A1/en not_active Abandoned
- 2010-03-26 JP JP2012502294A patent/JP2012521768A/ja active Pending
- 2010-03-26 WO PCT/US2010/028877 patent/WO2010111625A1/en not_active Ceased
- 2010-03-26 MX MX2011009810A patent/MX2011009810A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010111625A1 (en) | 2010-09-30 |
| CN102448984A (zh) | 2012-05-09 |
| EP2411407A1 (en) | 2012-02-01 |
| JP2012521768A (ja) | 2012-09-20 |
| US20120134993A1 (en) | 2012-05-31 |
| KR20110134494A (ko) | 2011-12-14 |
| AU2010229705A1 (en) | 2011-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011009810A (es) | Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor. | |
| KR20200093639A (ko) | 천연 항체 구조-유사 헤테로다이머 형태의 항 pd-l1/항 cd47 이중특이성 항체 및 이의 제조 | |
| EP4249064A2 (en) | Novel fusion protein specific for cd137 and pd-l1 | |
| NZ627103A (en) | Specific binding proteins and uses thereof | |
| GEP20115324B (en) | Tweak binding antibodies | |
| CA2926262A1 (en) | Cysteine engineered fibronectin type iii domain binding molecules | |
| JP2015516813A5 (OSRAM) | ||
| PH12020500137A1 (en) | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods | |
| JP2016525551A5 (OSRAM) | ||
| MX2012005864A (es) | Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas. | |
| PH12013500050A1 (en) | Anticancer fusion protein | |
| JP2013529070A (ja) | Ｔｒａｉｌｒ２特異的多量体足場 | |
| MX2010009190A (es) | Anticuerpos anti-c5ar humanizados. | |
| KR20210133254A (ko) | Cd137 및 gpc3에 특이적인 신규한 융합 단백질 | |
| WO2013184960A3 (en) | Chimeric fibroblast growth factor 23 proteins and methods of use | |
| EP2498799A4 (en) | USE OF FGFR1 EXTRACELLULAR DOMAIN PROTEINS TO TREAT CANCERS CHARACTERIZED BY LIGAND-DEPENDENT ACTIVATION MUTATIONS IN FGFR2 | |
| TW200801036A (en) | RAGE fusion proteins, formulations, and methods of use thereof | |
| RU2015152077A (ru) | Тримерные антигенсвязывающие молекулы | |
| IN2012DN02981A (OSRAM) | ||
| NZ601591A (en) | Methods for treating pancreatic cancer | |
| RU2013140472A (ru) | Слитый белок антиангиогенного индуцирующего фактора и его применение | |
| NZ615070A (en) | Npp1 fusion proteins | |
| WO2020247388A3 (en) | Il-2alpha receptor subunit binding compounds | |
| RU2013140184A (ru) | Fgf-r-fc слитый белок и его использование | |
| NO20064134L (no) | Modifiserte bouganinproteiner, cytotoksiner og fremgangsmater og anvendelser derav |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |